Scarica l'app Stockscreener
1.18
3.28%
-0.04
Dopo l'orario di chiusura:
1.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BCLI Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$1.22
Aprire:
$1.2
Volume 24 ore:
117.45K
Relative Volume:
0.74
Capitalizzazione di mercato:
$8.22M
Reddito:
-
Utile/perdita netta:
$-16.63M
Rapporto P/E:
-2.7442
EPS:
-0.43
Flusso di cassa netto:
$-21.84M
1 W Prestazione:
-6.35%
1M Prestazione:
+5.88%
6M Prestazione:
-1.67%
1 anno Prestazione:
-83.15%
Intervallo 1D:
$1.13
$1.2484
Intervallo di 1 settimana:
$1.13
$1.37
Portata 52W:
$0.7233
$10.05
Brainstorm Cell Therapeutics Inc Stock (BCLI) Company Profile
Nome
Brainstorm Cell Therapeutics Inc
Settore
Industria
Telefono
201-488-0460
Indirizzo
1325 AVENUE OF AMERICAS, NEW YORK, NY
Confronta BCLI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCLI
Brainstorm Cell Therapeutics Inc
|
1.18 | 8.22M | 0 | -16.63M | -21.84M | -0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Brainstorm Cell Therapeutics Inc Stock (BCLI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-02-04 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-11-17 | Downgrade | Maxim Group | Buy → Hold |
| 2016-12-19 | Reiterato | Maxim Group | Buy |
| 2015-12-22 | Reiterato | Maxim Group | Buy |
Brainstorm Cell Therapeutics Inc Borsa (BCLI) Ultime notizie
Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q4 2024 Earnings Call Transcript - MSN
Stem Cell Therapy Market 2025: Technical Signs Point Higher Growth Levels - newstrail.com
SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BrainStorm Cell Therapeutics to Announce First Quarter Results and Provide a Corporate Update on May 15, 2025 - Stock Titan
BrainStorm's ALS Treatment Breakthrough: New Biomarker Data Shows Promise as FDA-Approved Trial Approaches - Stock Titan
StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Geode Capital Management LLC Sells 630,315 Shares of Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) - Defense World
5 Best Stem Cell Companies to Invest In (May 2025) - Securities.io
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR ALERT: Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 2, 2024 in Brainstorm Cell LawsuitBCLI - ACCESS Newswire
BCLI’s Market Whiplash: -50.66% YTD Decline, -17.04% Plunge in 30 Days - investchronicle.com
BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting - marketscreener.com
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com - Defense World
Stem Cell Therapy Market Size, Share & Trends Analysis 2025-2032 | Osiris Therapeutics, Inc., Kolon TissueGene - newstrail.com
Brainstorm Cell Therapeutics adjusts quorum requirement By Investing.com - Investing.com India
Brainstorm Cell Therapeutics adjusts quorum requirement - Investing.com
StockNews.com Initiates Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World
Brainstorm Cell Therapeutics (NASDAQ:BCLI) Earns Hold Rating from Analysts at StockNews.com - American Banking and Market News
Brainstorm seeks FDA OK to launch NurOwn Phase 3b trial in ALS - ALS News Today
BrainStorm advances ALS therapy with FDA trial submission By Investing.com - Investing.com South Africa
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
BrainStorm advances ALS therapy with FDA trial submission - Investing.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS - Nasdaq
Indo-Asian News Service - Indo-Asian News Service (IANS)
BrainStorm Cell Therapeutics (BCLI)Fundamentals Update 09042025 - Smartkarma
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Stacy Lindborg, PhD's Profile Page - Technology Networks
BrainStorm Cell Therapeutics Reports 2024 Financial Results - TipRanks
BrainStorm Cell Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Earnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cutting - Investing.com Canada
Earnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cutting By Investing.com - Investing.com South Africa
Brainstorm Cell Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
BRAINSTORM CELL THERAPEUTICS INC. SEC 10-K Report - TradingView
SEC Form 10-K filed by Brainstorm Cell Therapeutics Inc. - Quantisnow
Brainstorm Cell Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits - Quantisnow
BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - Nasdaq
INVESTOR ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock DropLevi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Brainstorm Cell Therapeutics (BCLI) to Release Earnings on Monday - Defense World
Brainstorm Cell Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Brainstorm Cell Therapeutics gains extension from Nasdaq - Investing.com
Brainstorm Cell Therapeutics gains extension from Nasdaq By Investing.com - Investing.com India
BrainStorm Cell Therapeutics Granted Compliance Extension from N - GuruFocus.com
BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq - MarketScreener
BrainStorm Wins Critical Nasdaq Extension: New ALS Study and Strategic Plans Unveiled - Stock Titan
Brainstorm Cell Therapeutics Inc Azioni (BCLI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.84%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):